Decreased synthesis of tissue plasminogen activator antigen in users of oral contraceptives

Fibrinolysis and Proteolysis

Volumn 14, Issue 5, 2000, Pages 315-321

  Petersen, K R ^a   Jorgensen M ^a   Vinberg, N ^b   Gram, J ^b   Skouby, S O ^c   Tonnesen K H ^c   Jespersen, J ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c DANISH MEDICINES AGENCY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL; GESTODENE; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HORMONAL CONTRACEPTION; HUMAN; ORAL CONTRACEPTION; PLASMA VOLUME; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; THROMBOSIS;

EID: 0033825518     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0089     Document Type: Article

References (31)

1. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994; 59: 233-255.
2. Chandler WL, Wayne CL, Levy C, Stratton JR. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984-2994.
3. Wiman B. Plasminogen activator inhibitor (PAI-1) in plasma: Its role in thrombotic disease. Throrab Haemostas 1995; 74: 71-76.
4. Jespersen J, Munkvad S, Gram J. The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima. Dan Med Bull 1993; 40: 495-502.
5. Biessen EAL, van Teijlingen M, Vietsch et al. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997; 95: 46-52.
6. Strickland DK, Kounnan MZ, Williams SE, Argraves WS. LDL receptor-related protein (LPR): A mukiligand receptor. Fibrinolysis 1994; 8(suppl 1): 204-215.
7. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-208.
8. Petaja J, Rasi V, Myllyla G, Vahhtera E, Hallman H. Familial hypofibrinolysis and venous thrombosis. Br J Haematol 1989; 71: 393-398,
9. World Health Organization. Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series 877, 1998. WHO, Geneva, Switzerland.
10. Kluft C, Lansink M. Effects of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-326.
11. Siegbahn A, Ruusuvaara LA. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988; 60: 361-364.
12. Lindoff C, Peterson F, Lecander I, Martinsson G, Åstedt B. Passage of the menopause is followed by hemostatic changes. Maturitas 1993; 17: 17-22.
13. Shahar E, Folsom AR, Salomaa W et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996; 93: 1970-1975.
14. vanKesteren PJM, Kooistra T, Lansink M et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029-1033.
15. Lansink M, Jong M, Bijsterbosch M et al. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. Blood 1999; 94: 1330-1336.
16. Ma PTS, Yamamoto, Goldstein JL, Brown MS. Increased mRNA for low density lipoprotein receptors in livers of rabbits treated with 17-alpha ethinyl estradiol. Proc NatI Acad Sci USA 1986; 83: 792-796.
17. Kooistra T, Bosma PJ, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-412.
18. Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 Hg and 30 μg Ethinylestradiol. Contraception 1996; 53: 75-84.
19. Giltay EJ, Gooren LJG, Emeis JJ, Kooistra T, Stehouwer CDA. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 1396-1403.
20. Krishnamurthy GT, Turner FE. Pharmacokinetics and clinical application of Technetium 99m labelled hepatogenic agents. Semin Nucl Med 1990; 20: 130-149
21. Gram J, Jespersen J. A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma. Fibrinolysis 1987; 1: 33-37.
22. Meyer P, Zierler KL. On the theory of the indicator - dilution method for measurement of blood flow and volume. J Appl Physiol 1954; 6: 731-736.
23. Tønnesen KH, Sejrsen P. Inert gas diffusion method for measurement of blood flow. Circulation Res 1967; 20: 552-564.
24. Lassen NA, Pearl W. Tracer Kinetic Methods in Medical Physiology. New York: Raven Press, 1979: 1-13.
25. Freimann JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 1978; 299: 690-694.
26. Oparil C. Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Hypertension 1999; 33: 170-176.
27. Keber D, Stegnar M, Kluft C. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Thromb Haemost 1990; 93: 72-75.
28. van Griensven JMT, Huisman LGM, Stuurman T et al. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60: 504-511.
29. Brommer EJ, Derks HMF, Schaalekamp MADH, Dooijewaard G, Klaauw MDV. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man. Thromb Haemost 1988; 59: 404-411.
30. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 189-215.
31. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague J. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 3: 761-768.